PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma

被引：0
|
作者：
Yael Babichev
Leah Kabaroff
Alessandro Datti
David Uehling
Methvin Isaac
Rima Al-awar
Michael Prakesch
Ren X. Sun
Paul C. Boutros
Rosemarie Venier
Brendan C. Dickson
Rebecca A. Gladdy
机构：
[1] Mount Sinai Hospital,Lunenfeld
[2] Lunenfeld-Tanenbaum Research Institute,Tanenbaum Research Institute
[3] University of Perugia,Sinai
[4] Ontario Institute for Cancer Research,McLaughlin Assay and Robotic Technologies Facility
[5] University of Toronto,Department of Agricultural, Food, and Environmental Sciences
[6] Ontario Institute for Cancer Research,Drug Discovery Group
[7] University of Toronto,Department of Pharmacology and Toxicology
[8] Mount Sinai Hospital,Informatics and Biocomputing Program
[9] University of Toronto,Department of Medical Biophysics
[10] University of Toronto,Department of Pathology and Laboratory Medicine
[11] Ontario Institute for Cancer Research,Department of Surgery
[12] Lunenfeld-Tanenbaum Research Institute,Institute of Medical Science
来源：
Journal of Translational Medicine | / 14卷
关键词：
Leiomyosarcoma; PI3K; mTOR; Drug discovery; Sarcoma; Doxorubicin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma
    Babichev, Yael
    Kabaroff, Leah
    Datti, Alessandro
    Uehling, David
    Isaac, Methvin
    Al-awar, Rima
    Prakesch, Michael
    Sun, Ren X.
    Boutros, Paul C.
    Venier, Rosemarie
    Dickson, Brendan C.
    Gladdy, Rebecca A.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [2] Therapeutic Potential of PI3K/Akt/mTOR Signalling Pathway: Effective Combination Therapy for Cancer
    Kawade, V. S.
    Satpute, P. S.
    Dhulap, S. A.
    Gurjar, S.
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 80 (04) : 702 - 708
  • [3] PI3K/AKT/mTOR
    Umemura, Shigeki
    Goto, Koichi
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S116 - S117
  • [4] Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
    Prasad, Gautam
    Sottero, Theo
    Yang, Xiaodong
    Mueller, Sabine
    James, C. David
    Weiss, William A.
    Polley, Mei-Yin
    Ozawa, Tomoko
    Berger, Mitchel S.
    Aftab, Dana T.
    Prados, Michael D.
    Haas-Kogan, Daphne A.
    NEURO-ONCOLOGY, 2011, 13 (04) : 384 - 392
  • [5] Inhibition of PI3K/AKT/mTOR pathway for the treatment of endometriosis
    Barra, Fabio
    Desideri, Lorenzo Ferro
    Ferrero, Simone
    BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (17) : 3626 - 3627
  • [6] Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
    LoRusso, Patricia Mucci
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) : 3803 - +
  • [7] Inhibition of PI3K/Akt/mTOR Signaling by Natural Products
    Huang, Shile
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2013, 13 (07) : 967 - 970
  • [8] Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy
    Wani, Atif Khurshid
    Singh, Reena
    Akhtar, Nahid
    Prakash, Ajit
    Nepovimova, Eugenie
    Oleksak, Patrik
    Chrienova, Zofia
    Alomar, Suliman
    Chopra, Chirag
    Kuca, Kamil
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2024, 24 (16) : 1496 - 1520
  • [9] Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway
    Morgan, Todd M.
    Koreckij, Theodore D.
    Corey, Eva
    CURRENT CANCER DRUG TARGETS, 2009, 9 (02) : 237 - 249
  • [10] PI3K/Akt/mTOR pathway as a target for cancer therapy
    Morgensztern, D
    McLeod, HL
    ANTI-CANCER DRUGS, 2005, 16 (08) : 797 - 803
12345